FAMAR Group has signed a contract manufacturing agreement with GE HealthCare to fill and finish vials of GE HealthCare's iodine-based contrast media, at its newly acquired site in Homburg, Germany, with commercial supply due to begin in 2028.
This agreement will enable GE HealthCare to expand its manufacturing capacity for Europe-based customers of its iodine-based contrast media, used in Computed Tomography, X-Ray, and interventional imaging to enhance visualization of organs, blood vessels and tissues to support clinical diagnosis. The Homburg site is targeted to provide up to 25 million patient doses, annually, into GE HealthCare's supply network by 2031.
Dr. Riku Rautsola, CEO of the FAMAR Group, said: "The Homburg site will provide world-class manufacturing with scalable capacity. We are proud to be working with GE HealthCare and, over time, other businesses at the Homburg site, to provide manufacturing at the highest of standards to support their evolving needs."
FAMAR Group acquired the Homburg site from MiP Pharma in September 2025 and plans to develop it into a multi-customer CDMO platform, strengthening its footprint in high-value dosage forms, expanding its capabilities in aseptic and lyophilized fill & finish and becoming the centre of excellence for sterile supply.
François Roche, General Manager, EMEA, for GE HealthCare's Pharmaceutical Diagnostics (PDx) segment, said: "This agreement will enable us to continue to scale up production capacity for our European customers to meet increasing demand, while also further increasing the resiliency of our network."